Nautilus Biotechnology (NAUT)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity...
- Open
- 0.9000
- High
- 0.9800
- Low
- 0.8900
- Prev. Close
- 0.8857
- Volume
- 785.26K
- Turnover
- 746.80K
- Avg Price
- 0.9510
- Bid/Ask Ratio
- 22.70%
- Amplitude
- 10.16%
- 52wk High
- 4.3100
- Volume Ratio
- 1.53
- Turnover Ratio
- 1.31%
Nautilus Biotechnology Analyst Rating
View moreForecast & Rating
Jul 28, 2026Price forecast
$4.00311.35%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Aug 24 at 12:21 PM
Undervalued Penny Stocks To Consider In August 2026
- Unusual Whales · Jul 28 at 07:06 AM
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
- Quartr · Jul 28 at 05:05 AM
NAUT: First revenue achieved and net loss narrowed as proteoform assay development accelerates
- PUBT · Jul 8 at 07:00 AM
Nautilus Biotechnology to report Q2 results, host conference call
- benzinga_article · Jul 6 at 05:11 AM
Top 3 Health Care Stocks That May Rocket Higher In July
- PUBT · Jun 18 at 03:06 PM
Nautilus Biotechnology shareholders elect Class II directors Mallick, Nazem at annual meeting
